Morgan Stanley (MS)
216.40
+0.00 (0.00%)
NYSE· Last Trade: Jul 22nd, 5:17 AM EDT
The memory sell-off ran into a forecast it couldn't argue with.
Via The Motley Fool · July 22, 2026
Declining take rates and a CEO switch weighed on the stock.
Via The Motley Fool · July 22, 2026
Alternative investment manager Blackstone (NYSE:BX) will be reporting earnings this Thursday before market hours. Here’s what you need to know. Blackstone be...
Via StockStory · July 21, 2026
Financial advisory firm Lazard (NYSE:LAZ) will be announcing earnings results this Thursday before the bell. Here’s what investors should know. Lazard missed...
Via StockStory · July 21, 2026
What Happened? Shares of website building platform Wix (NASDAQ:WIX) fell 2.7% in the afternoon session after Morgan Stanley downgraded the stock's rating fro...
Via StockStory · July 21, 2026
What Happened? Shares of search AI platform provider Elastic (NYSE:ESTC) fell 4.4% in the afternoon session after Morgan Stanley downgraded the company's sto...
Via StockStory · July 21, 2026
What Happened? Shares of creative software giant Adobe (NASDAQ:ADBE) fell 3.5% in the afternoon session after Morgan Stanley downgraded the stock's rating to...
Via StockStory · July 21, 2026
One Wall Street analyst says the company's AI transition isn't happening fast enough.
Via The Motley Fool · July 21, 2026
The future looks bright for these companies, but that doesn't make them automatic buys right now.
Via The Motley Fool · July 21, 2026
All three major indexes are climbing together for a change. Semiconductor stocks deserve most of the credit.
Via The Motley Fool · July 21, 2026
What Happened? Shares of enterprise software company Workday (NASDAQ:WDAY) fell 2.5% in the morning session after two Wall Street firms issued bearish calls,...
Via StockStory · July 21, 2026
What Happened? Shares of financial automation software company BlackLine (NASDAQ:BL) fell 3.5% in the morning session after Morgan Stanley downgraded the sto...
Via StockStory · July 21, 2026
What Happened? Shares of digital operations platform PagerDuty (NYSE:PD) fell 7.2% in the morning session after Morgan Stanley downgraded the stock to Underw...
Via StockStory · July 21, 2026
What Happened? Shares of cybersecurity software provider Rapid7 (NASDAQ:RPD) fell 11.3% in the morning session after Morgan Stanley downgraded the company's ...
Via StockStory · July 21, 2026
Salesforce, Inc. (NYSE: CRM) stock is declining Monday after Morgan Stanley downgraded the cloud software provider to Equal-Weight and cut its price forecast to $185.
Via Benzinga · July 21, 2026
Adobe Inc. (NASDAQ: ADBE) stock declined Monday after Morgan Stanley downgraded the company from Equal-Weight to Underweight and lowered its price target to $240.
Via Benzinga · July 21, 2026
Sandisk stock pops 7% on rising AI memory demand and bullish analyst forecasts. Get key SNDK price targets and ETF exposure insights.
Via Benzinga · July 21, 2026
Investment analytics provider MSCI (NYSE:MSCI) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 12.2% year on year to $867 million. Its non...
Via StockStory · July 21, 2026
Sarat Sethi recommends Morgan Stanley (MS), Stephen Weiss picks Goldman Sachs (GS) and Joseph M. Terranova chooses Valero Energy (VLO).
Via Benzinga · July 21, 2026
Most Wall Street analysts believe Alphabet stock is undervalued.
Via The Motley Fool · July 21, 2026
Financial services firm Raymond James Financial (NYSE:RJF) will be reporting results this Wednesday afternoon. Here’s what investors should know. Raymond Jam...
Via StockStory · July 20, 2026
Financial services firm Stifel Financial (NYSE:SF) will be reporting earnings this Wednesday before the bell. Here’s what to expect. Stifel met analysts’ rev...
Via StockStory · July 20, 2026
Micron is flush with cash, and could buy back 40% of its stock by 2028.
Via The Motley Fool · July 20, 2026
Sandisk stock is still cyclical, but the end of this cycle looks a long way off.
Via The Motley Fool · July 20, 2026
Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities.
On a call with analysts, Tempus said it agreed to acquire all ou
Via MarketBeat · July 20, 2026